

REMARKS

The present invention is directed to methods of treating undesired angiogenesis with 2-methoxyestradiol. Claims 1-25 were filed originally. With this response, Claims 1-25 have been canceled, and Claims 26-42 have been added. Thus, following these amendments, Claims 26-42 are pending. No new matter has been added with these amendments and their support can be found generally within the specification.

Restriction Requirement

Responsive to the Restriction Requirement mailed January 28, 2002 in the above-identified patent application, Applicants are required to elect an invention. Accordingly, Applicants elect the invention of Group I, claims 1, 13-18 and 24 (in part), drawn to a method for treating a mammalian disease by administering a compound of the formula shown wherein Z" is Y and Y is oxygen, classified in class 514, subclass 449+.

However, by this amendment, Applicants have canceled Claims 1-25 and added claims 26-42.

Preliminary Amendment

Prior to examination of the above-referenced application, applicants respectfully request entry of the amendments as indicated above.

No additional fees are believed due, however, the Commissioner is hereby authorized to charge any deficiency, or credit any overpayment to Deposit Account No. 11-0855.

CONCLUSION

In light of the amendments Applicants are of the opinion that the Restriction Requirement has been completely responded to and that the application (or specific claims) is/are now in condition for allowance. Such action is respectfully requested. If the Examiner believes any informalities remain in the application which may be corrected by Examiner's Amendment, or there are any other issues which can be resolved by telephone interview, a telephone call to the undersigned attorney at (404) 745-2413 is respectfully solicited.

Respectfully submitted,

KILPATRICK STOCKTON LLP



By: Suzanne Seavello Shope
Reg. No. 37,933

Kilpatrick Stockton LLP
Suite 2800
1100 Peachtree Street
Atlanta, GA 30309-4530
Tel. 404.815.6500

February 28, 2002
Our File: 05213-0493 (43170-253692)